SynthesisThe oncologist2025

Comparative efficacy and safety of talazoparib plus enzalutamide and other first-line treatments for metastatic castration-resistant prostate cancer.

Elena Castro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.